What is the share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) today?
The share price of JAGSNPHARM as on 1st February 2026 is ₹169.07. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The past returns of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share are- Past 1 week: 1.54%
- Past 1 month: -12.66%
- Past 3 months: -24.13%
- Past 6 months: -37.69%
- Past 1 year: -31.68%
- Past 3 years: 22.28%
- Past 5 years: 465.45%
What are the peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?
The peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) include:What is the dividend yield % of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The current dividend yield of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 1.47.What is the market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹1129.24 Cr as of 1st February 2026.What is the 52 week high and low of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The 52-week high of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹301.65 and the 52-week low is ₹155.What is the PE and PB ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) stock?
The P/E (price-to-earnings) ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 20.39. The P/B (price-to-book) ratio is 4.71.Which sector does Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belong to?
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares?
You can directly buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Jagsonpal Pharmaceuticals Ltd
JAGSNPHARM Share Price
169.070.15% (+0.25)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
JAGSNPHARM Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
JAGSNPHARM Performance & Key Metrics
JAGSNPHARM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 27.63 | 4.71 | 1.47% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 34.76 | 5.52 | 0.62% |
JAGSNPHARM Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
JAGSNPHARM Company Profile
Jagsonpal Pharmaceuticals Limited is engaged in pharmaceutical business. It specializes in developing and manufacturing bulk drugs and pharmaceutical formulations.
SUNPHARMA
PE Ratio
35.02
35.02
1Y Return
7.58%
7.58%
Buy Reco %
94.44
94.44
TORNTPHARM
PE Ratio
70.14
70.14
1Y Return
24.61%
24.61%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
20.28
20.28
1Y Return
7.68%
7.68%
Buy Reco %
58.06
58.06
DRREDDY
PE Ratio
17.93
17.93
1Y Return
2.18%
2.18%
Buy Reco %
50.00
50.00
LUPIN
PE Ratio
29.98
29.98
1Y Return
3.84%
3.84%
Buy Reco %
72.22
72.22
JAGSNPHARM Sentiment Analysis
JAGSNPHARM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
JAGSNPHARM Stock Summary · January 2026
In Q3 FY26, the company demonstrated resilience with a 6% revenue growth and a 13% increase in net income, despite facing challenges in its Regional Pharmaceutical Market and a broader industry slowdown. Management is optimistic about a return to double-digit growth, driven by strategic initiatives such as enhancing its presence in branded generics and expanding into underserved therapeutic areas. While operational adjustments have caused near-term disruptions, efforts to improve productivity and rationalize underperforming brands are underway. The recent acquisition of Yash Pharma is expected to bolster future performance, and proactive measures are being taken to address market share erosion amid shifting prescription trends. Overall, the company is well-positioned to adapt to evolving market dynamics while maintaining a focus on long-term organic growth.
JAGSNPHARM Stock Growth Drivers
JAGSNPHARM Stock Growth Drivers
6Resilient Financial Performance
Jagsonpal Pharmaceuticals has demonstrated a resilient financial performance with a 6% growth in revenue and
Strategic Leadership Changes
The company has undergone significant leadership changes aimed at enhancing long-term growth. New appointments in
JAGSNPHARM Stock Challenges
JAGSNPHARM Stock Challenges
5Impact of New Labor Code
The company has accounted for a one-time exceptional expense of INR 2.1 crores due to
Muted Revenue Growth
The company reported a revenue growth of only 6%, which is below expectations, indicating a
JAGSNPHARM Forecast
JAGSNPHARM Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
JAGSNPHARM
JAGSNPHARM
Income
Balance Sheet
Cash Flow
Annual Normal View
JAGSNPHARM Income Statement
JAGSNPHARM Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 157.14 | 126.99 | 168.26 | 161.10 | 192.34 | 221.01 | 242.44 | 217.98 | 300.27 | 293.18 | ||||||||||
Raw Materials | 67.34 | 65.19 | 53.43 | 54.94 | 75.50 | 83.35 | 88.04 | 76.08 | 98.56 | 228.25 | ||||||||||
| Power & Fuel Cost | 2.12 | 1.00 | 1.41 | 0.64 | 0.52 | 0.47 | 0.29 | 0.17 | 0.19 | |||||||||||
| Employee Cost | 40.95 | 41.88 | 46.61 | 50.37 | 53.98 | 57.68 | 65.18 | 62.09 | 70.93 | |||||||||||
| Selling & Administrative Expenses | 30.19 | 27.56 | 32.23 | 38.34 | 31.88 | 42.50 | 41.66 | 40.80 | 48.54 | |||||||||||
| Operating & Other expenses | -2.50 | 2.01 | 23.81 | 5.75 | 6.99 | 8.56 | 10.85 | 6.50 | 3.09 | |||||||||||
EBITDA | 19.04 | -10.65 | 10.77 | 11.06 | 23.47 | 28.45 | 36.42 | 32.34 | 78.96 | 64.93 | ||||||||||
| Depreciation/Amortization | 1.99 | 0.32 | 1.02 | 1.13 | 1.09 | 1.53 | 1.21 | 1.66 | 8.13 | 9.44 | ||||||||||
| PBIT | 17.05 | -10.97 | 9.75 | 9.93 | 22.38 | 26.92 | 35.21 | 30.68 | 70.83 | 55.49 | ||||||||||
| Interest & Other Items | 2.64 | 0.66 | 0.75 | 0.51 | 0.51 | 0.29 | 0.41 | 0.81 | 0.96 | 1.04 | ||||||||||
| PBT | 14.41 | -11.63 | 9.00 | 9.42 | 21.87 | 26.63 | 34.80 | 29.87 | 69.87 | 54.45 | ||||||||||
| Taxes & Other Items | 2.53 | -0.08 | 1.78 | 1.54 | 4.82 | 7.78 | 8.09 | 7.41 | 14.50 | 13.58 | ||||||||||
| Net Income | 11.88 | -11.55 | 7.22 | 7.88 | 17.05 | 18.85 | 26.71 | 22.46 | 55.37 | 40.87 | ||||||||||
| EPS | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.41 | 8.36 | 6.16 | ||||||||||
| DPS | 0.04 | 0.04 | 0.10 | 0.20 | 0.40 | 1.60 | 2.00 | 2.00 | 2.50 | 2.50 | ||||||||||
| Payout ratio | 0.02 | 0.00 | 0.09 | 0.17 | 0.15 | 0.56 | 0.49 | 0.59 | 0.30 | 0.41 |
JAGSNPHARM Company Updates
FY 2026FY 2026
Investor Presentation
Jan 21PDF
Nov 3PDF
Jul 26PDF
JAGSNPHARM Stock Peers
JAGSNPHARM Past Performance & Peer Comparison
JAGSNPHARM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd | 20.39 | 4.71 | 1.47% |
| Sun Pharmaceutical Industries Ltd | 35.02 | 5.28 | 1.00% |
| Torrent Pharmaceuticals Ltd | 70.14 | 17.66 | 0.81% |
| Cipla Ltd | 20.28 | 3.42 | 1.21% |
JAGSNPHARM Stock Price Comparison
Compare JAGSNPHARM with any stock or ETFCompare JAGSNPHARM with any stock or ETF
JAGSNPHARM
JAGSNPHARM Holdings
JAGSNPHARM Shareholdings
JAGSNPHARM Promoter Holdings Trend
JAGSNPHARM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
JAGSNPHARM Institutional Holdings Trend
JAGSNPHARM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
JAGSNPHARM Shareholding Pattern
JAGSNPHARM Shareholding Pattern
JAGSNPHARM Shareholding History
JAGSNPHARM Shareholding History
Foreign Institutions
Mutual Funds Invested in JAGSNPHARM
Mutual Funds Invested in JAGSNPHARM
No mutual funds holding trends are available
Top 1 Mutual Funds holding Jagsonpal Pharmaceuticals Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.03% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 113/123 (-3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing JAGSNPHARM stock
smallcases containing JAGSNPHARM stock
Looks like this stock is not in any smallcase yet.
JAGSNPHARM Events
JAGSNPHARM Events
JAGSNPHARM Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
JAGSNPHARM has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.47%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹14.70 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
JAGSNPHARM Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
JAGSNPHARM has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.47%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹14.70 every year
JAGSNPHARM Upcoming Dividends
JAGSNPHARM Upcoming Dividends
No upcoming dividends are available
JAGSNPHARM Past Dividends
JAGSNPHARM Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2025
Final
Final | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Sep 12, 2025
Cash Dividend
Ex DateEx DateSep 6, 2024
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Sep 6, 2024
Cash Dividend
Ex DateEx DateAug 21, 2023
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 21, 2023
Cash Dividend
Ex DateEx DateOct 29, 2021
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Oct 29, 2021
Cash Dividend
Ex DateEx DateSep 22, 2021
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 22, 2021
JAGSNPHARM Stock News & Opinions
JAGSNPHARM Stock News & Opinions
Articles & Videos
Earnings
Jagsonpal Pharmaceuticals standalone net profit declines 65.77% in the December 2025 quarter
Net profit of Jagsonpal Pharmaceuticals declined 65.77% to Rs 10.95 crore in the quarter ended December 2025 as against Rs 31.99 crore during the previous quarter ended December 2024. Sales declined 1.46% to Rs 72.95 crore in the quarter ended December 2025 as against Rs 74.03 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales72.9574.03 -1 OPM %22.3021.38 - PBDT18.9917.90 6 PBT16.6015.49 7 NP10.9531.99 -66 Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals schedules board meeting
Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 21 January 2026.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 1.09 lakh equity shares under ESOP
Jagsonpal Pharmaceuticals has allotted 1,09,180 equity shares under ESOP. With this allotment, the paid up equity share capital has increased to Rs. 13,37,80,900 (constituting of 6,68,90,450 equity shares of Rs. 2/- each). Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 56,571 equity shares under ESOP
Jagsonpal Pharmaceuticals has allotted 56,571 equity shares under ESOP on 18 November 2025. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,34,49,398 (constituting of 6,67,24,699 equity shares of Rs. 2/- each) to Rs. 13,35,62,540 (constituting of 6,67,81,270 equity shares of Rs. 2/- each).Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Jagsonpal Pharmaceuticals standalone net profit rises 9.69% in the September 2025 quarter
Net profit of Jagsonpal Pharmaceuticals rose 9.69% to Rs 12.57 crore in the quarter ended September 2025 as against Rs 11.46 crore during the previous quarter ended September 2024. Sales declined 0.29% to Rs 74.47 crore in the quarter ended September 2025 as against Rs 74.69 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales74.4774.69 0 OPM %22.0821.81 - PBDT19.2017.71 8 PBT16.8115.37 9 NP12.5711.46 10 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals to declare Quarterly Results
Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 3 November 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Jagsonpal Pharma appoints Nirav Vora as CFO
The appointment was made based on the recommendations of the company's nomination and remuneration committee and audit committee, and subsequently approved by the board. Vora is a Commerce graduate and a member of the Institute of Chartered Accountants of India (ICAI). He brings with him over 18 years of experience in finance, taxation, and allied laws, having worked across diverse industries. Jagsonpal Pharmaceuticals engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients. The company's standalone net profit jumped 38.6% to Rs 10.80 crore on 23.1% rise in revenue from operations to Rs 75.61 crore in Q1 FY26 over Q1 FY25. Shares of Jagsonpal Pharma shed 0.46% to Rs 214.90 on the BSE. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 93,445 equity shares under ESOP
Jagsonpal Pharmaceuticals has allotted 93,445 equity shares under ESOP on 07 October 2025. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,32,62,508 (constituting of 6,66,31,254 equity shares of Rs. 2/- each) to Rs. 13,34,49,398 (constituting of 6,67,24,699 equity shares of Rs. 2/- each).Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 66,000 equity shares under ESOP
Jagsonpal Pharmaceuticals has allotted 66,000 equity shares of Rs. 2/- each under JPL ESOP 2022, to the eligible employees of the Company, upon exercise of vested options. These shares shall rank Pari-passu with the existing equity shares of the Company, in all respects. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,31,30,508 (constituting of 6,65,65,254 equity shares of Rs. 2/- each) to Rs. 13,32,62,508 (constituting of 6,66,31,254 equity shares of Rs. 2/- each).Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals AGM scheduled
Jagsonpal Pharmaceuticals announced that the 45th Annual General Meeting(AGM) of the company will be held on 24 September 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 13.26%, vs industry avg of 10.04%
Over the last 5 years, market share increased from 0.06% to 0.07%
Over the last 5 years, net income has grown at a yearly rate of 47.69%, vs industry avg of 20.02%